Actonel/Risedronate Once Weekly

For many people living with osteoporosis, the challenge of managing a long-term condition is as much about fitting treatment into daily life as it is about the medicine itself. Dosing frequency matters. Research into how patients take long-term oral medicines consistently shows that simpler schedules – those that require fewer discrete actions each week – support better adherence over time. Actonel/Risedronate Once Weekly 35mg Tablets are prescribed specifically on a once-weekly basis, offering the same active ingredient as the daily 5mg formulation but at a higher single dose taken on just one day per week.

Risedronate 35mg once weekly is licensed in the UK for the treatment of osteoporosis in postmenopausal women to reduce the risk of vertebral fractures. It is a Prescription Only Medicine. A clinical consultation with a registered prescriber is required before any supply can take place, and a prescription will only be issued where the prescriber determines the medicine is clinically appropriate for that individual.

Actonel Once Weekly is the branded form of risedronate sodium 35mg, formulated as a film-coated tablet taken once every seven days. Risedronate sodium is the active ingredient – a bisphosphonate that inhibits the cells responsible for breaking down bone. The once-weekly 35mg dose delivers a higher amount of active ingredient in a single administration than the 5mg daily formulation, but the total weekly exposure to the medicine is equivalent across both schedules.

The once-weekly regimen was developed in response to evidence that reducing the number of doses required per week improves treatment adherence without compromising clinical efficacy. For many postmenopausal women managing multiple prescriptions and conditions, a medicine taken once per week on a named day is easier to integrate into a consistent routine than one requiring daily attention.

The 35mg once-weekly formulation is specifically licensed for the treatment of osteoporosis in postmenopausal women to reduce the risk of vertebral fractures. This is a narrower indication than the daily 5mg formulation, which additionally covers men and patients on long-term corticosteroids. The prescriber will determine which risedronate formulation, strength, and schedule is appropriate based on the patient's diagnosis, fracture risk, and clinical history.

Generic risedronate sodium 35mg tablets are widely available as bioequivalent alternatives to branded Actonel. Both contain the same active ingredient at the same dose and are dispensed interchangeably within the licensed indication.

Bone remodelling is a continuous biological process. Throughout adulthood, osteoclast cells dissolve and remove small sections of ageing or damaged bone in a process called resorption. Osteoblast cells then deposit new mineralised tissue to fill the space. This cycle renews the skeleton progressively over years. In osteoporosis, the cycle becomes unbalanced: osteoclasts remove bone faster than osteoblasts can replace it.

After swallowing, risedronate is absorbed from the gut and transported to bone surfaces. It has a high affinity for hydroxyapatite, the mineral compound that gives bone its density and rigidity. Risedronate is taken up preferentially at sites where bone resorption is actively occurring. Within the osteoclast, it disrupts a cellular enzyme pathway – the mevalonate pathway – causing the osteoclast to lose its normal architecture and become functionally inactive.

A key feature of bisphosphonate pharmacokinetics is that the medicine does not simply circulate in the blood and wash out. Once incorporated into bone mineral, it remains embedded at that site until osteoclasts attempt to resorb that portion of bone. This means that individual doses continue to exert their effect over extended periods even though the medicine is only taken once weekly. The pharmacological effect on bone resorption is therefore sustained between doses.

Clinical studies of risedronate in postmenopausal women with osteoporosis have demonstrated statistically significant reductions in new vertebral fracture incidence. Changes in bone mineral density at the lumbar spine and hip are measurable from the early months of treatment and increase progressively with continued use. These changes underpin the medicine's licensed indication for fracture risk reduction.

Choose one day of the week that suits your routine and take one risedronate 35mg tablet on that day each week, at the same time of day. Consistency in choosing the same day each week is important. Some patients find it helpful to link the dose to a regular weekly activity – a set appointment or a weekly routine – to make it easier to remember.

Take the tablet first thing in the morning, before any food, any drink other than plain tap water, or any other oral medicine. Swallow the tablet whole with a full glass of plain tap water, at least 200ml. Do not use mineral water, fruit juice, dairy drinks, or any other beverage. These all reduce the absorption of risedronate, sometimes to a clinically significant degree.

Remain upright – sitting or standing – for at least thirty minutes after taking the tablet. Do not lie down or return to bed during this period. The tablet must not be taken at bedtime or before rising for the day. These precautions exist because risedronate can cause irritation of the oesophageal lining if it remains in contact with it for a prolonged period. Remaining upright and taking the tablet with adequate water significantly reduces this risk.

Do not eat, drink anything other than plain water, or take other oral medicines for at least thirty minutes after taking risedronate. Calcium supplements, antacids, iron tablets, and any product containing magnesium or aluminium must be taken at a different time of day – at least two hours should separate risedronate from these products.

If you forget your weekly dose, take it on the morning of the following day. After that, return to your usual weekly day. Never take two doses on the same day. If you vomit shortly after taking the tablet, do not repeat the dose. Continue your usual schedule the following week and inform your prescriber if vomiting is a recurring issue.

The Once-Weekly Formulation

Risedronate Once Weekly is available as a single 35mg film-coated tablet taken once every seven days. The table below summarises the licensed dosing schedule for this formulation.

How the Weekly 35mg Relates to Other Risedronate Formulations

The 35mg once-weekly tablet and the 5mg daily tablet deliver an equivalent total weekly dose of risedronate sodium. However, they have different licensed indications and are prescribed in different clinical contexts. The once-weekly 35mg formulation is licensed specifically for the treatment of osteoporosis in postmenopausal women to reduce vertebral fracture risk. The 5mg daily formulation carries additional licences covering men and glucocorticoid-induced bone loss.

Clinical note for the prescriber section: the once-weekly 35mg formulation should not be substituted for the daily 5mg formulation without clinical review, as their licensed indications differ. Patients who have been prescribed the daily formulation for glucocorticoid-induced osteoporosis should remain on that regimen unless their prescriber advises otherwise.

Vitamin D and Calcium

Prescribers often advise patients on risedronate to take a calcium and vitamin D supplement alongside their bisphosphonate treatment. Adequate calcium and vitamin D intake supports the mineralisation of new bone tissue and maximises the benefit of treatment. Supplements must always be taken at a separate time from risedronate – preferably several hours later – to avoid interference with absorption.

Take risedronate exactly as your prescriber has directed. Do not change your dosing schedule without first speaking to your prescriber.

Risedronate 35mg once weekly shares a broadly similar side effect profile to other risedronate formulations, with upper gastrointestinal effects being the most commonly reported. The following information is based on the current UK Summary of Product Characteristics.

Common Side Effects (may affect up to 1 in 10 people)

1. Abdominal pain, bloating, or discomfort
2. Nausea or feeling sick
3. Constipation or diarrhoea
4. Indigestion or heartburn
5. Bone, joint, or muscle pain
6. Headache

Uncommon Side Effects (may affect up to 1 in 100 people)

1. Oesophageal inflammation, erosion, or ulceration
2. Gastric or duodenal ulceration
3. Skin rash or itching
4. Eye inflammation, including uveitis or scleritis
5. Low blood calcium, particularly in patients with vitamin D deficiency

Rare and Serious Adverse Effects

The following serious adverse effects have been associated with bisphosphonate use, including risedronate. They are uncommon, but all patients should be aware of them.

1. Osteonecrosis of the jaw (ONJ): a rare but serious deterioration of jaw bone. The risk is elevated following invasive dental procedures. All patients taking risedronate should inform their dentist of their treatment before undergoing any dental work, including extractions and implant placement.
2. Atypical femoral fractures: stress fractures at unusual sites in the thigh bone, associated with prolonged bisphosphonate use. Patients who develop new, gradually worsening pain in the thigh, hip, or groin should report this to their prescriber promptly, as early identification is important.
3. Severe musculoskeletal pain: occasionally debilitating bone, joint, or muscle pain has been reported. This may resolve on discontinuation of treatment.
4. Severe skin reactions including Stevens-Johnson syndrome (very rare)

If you develop any new or worsening symptoms after starting risedronate, contact your prescriber. Do not stop taking the tablets without medical advice.

Report any side effects directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk, or through your prescriber or pharmacist.

Licensed Patient Group

The 35mg once-weekly formulation of risedronate is licensed specifically for the treatment of osteoporosis in postmenopausal women to reduce the risk of vertebral fractures. This is a defined patient group, and prescribing decisions will reflect the individual patient's fracture risk, bone density measurements, menopausal history, and any relevant comorbidities.

Postmenopausal women are particularly vulnerable to bone loss because oestrogen, which plays a central role in maintaining bone density, falls sharply after the menopause. This hormonal shift accelerates bone resorption and increases the risk of osteoporosis and associated fractures, particularly at the spine and hip. Age-related bone loss is a natural process, but for women whose bone density has declined to a clinically significant degree, prescription treatment may be warranted.

Who Should Not Take This Medicine

Risedronate 35mg once weekly should not be taken by patients with any of the following.

1. Uncorrected hypocalcaemia (low blood calcium) at the time of starting treatment
2. Severe renal impairment, defined as creatinine clearance below 30ml per minute
3. Known hypersensitivity to risedronate sodium or any excipient in the tablet formulation
4. Inability to remain upright for at least thirty minutes after taking the dose
5. Conditions affecting the oesophagus that impair its ability to empty normally, such as oesophageal stricture or achalasia

Risedronate is not licensed for use in men at the 35mg once-weekly dose, for children, or for the prevention or treatment of glucocorticoid-induced osteoporosis at this dose. Women who are pregnant or breastfeeding should not take risedronate.

Patients with mild to moderate renal impairment can generally take risedronate, but their prescriber should be aware of their renal function so that it can be factored into the prescribing decision. Patients with conditions affecting calcium metabolism, including vitamin D deficiency, should have these addressed before commencing bisphosphonate therapy.

A clinical consultation is the essential first step in obtaining risedronate 35mg once weekly. This medicine is a Prescription Only Medicine and cannot be supplied without a prescription issued by a registered prescriber. The consultation exists to establish whether this treatment is clinically appropriate for you. A prescription is a possible outcome of the consultation, not a predetermined one.

Through Pharmacy Planet's online consultation, you will be asked to provide information about your diagnosis, your menopausal status and history, any previous fractures, your current and recent medicines, and relevant medical conditions. A UK registered prescriber will review this information and make a clinical determination about whether risedronate 35mg once weekly is appropriate for you at this time.

Women seeking treatment for osteoporosis through an online pharmacy are often those already established on a prescribed regimen who require a convenient route for ongoing supply. In these circumstances, the prescriber will confirm that continued treatment remains appropriate and that no new clinical concerns have arisen since the original diagnosis and prescribing decision.

If the prescriber requires additional clinical information – for example, confirmation of a recent DEXA scan result or clarification of a medical history point – you will be informed and guided on how to provide it. Pharmacy Planet's pharmacy team is available to assist with any queries about the consultation process.

Store risedronate 35mg tablets in a dry place below 25 degrees Celsius. Keep the tablets in their original blister packaging. Blister strips protect each tablet individually from moisture and light, which can degrade the film coating and affect tablet integrity over time.

Once-weekly dosing means that a single pack of risedronate covers a longer period than most daily oral medicines. This makes it all the more important to check the expiry date on the blister strip and packaging regularly. Expired tablets should not be taken. The date printed on the packaging refers to the last day of the month shown.

Keep all medicines, including risedronate, out of the sight and reach of children. Return any unused or out-of-date tablets to a pharmacy for safe disposal. Medicines must not be placed in household refuse or flushed into drains.

All seven medicines listed below are oral tablets or capsules prescribed for osteoporosis, the same therapeutic category and the same form factor, making direct comparison appropriate. They differ in their active ingredient, dosing frequency, licensed indication, and mechanism of action.

The table below compares commonly prescribed oral bisphosphonate treatments available through Pharmacy Planet's osteoporosis service. Products are listed in order of dosing frequency, from daily to monthly, so you can quickly identify how each medicine fits into a patient's routine.

Important: This comparison is for general information only and does not replace medical advice. A prescriber will decide which treatment is suitable for you following an online consultation. All medicines listed are Prescription Only Medicines (POMs). Suitability depends on individual clinical circumstances including diagnosis, renal function, medical history, and concurrent medicines.

Pharmacy Planet is a GPhC-registered online pharmacy providing regulated prescription services to patients across the UK. We work to the clinical and operational standards expected of a registered pharmacy, and every prescription we dispense is reviewed by a qualified pharmacist before it leaves our dispensary.

We recognise that for patients managing osteoporosis over years or decades, reliable access to ongoing prescriptions matters. Our consultation and repeat dispensing service is designed to be straightforward, private, and clinically rigorous – giving patients a dependable route to the medicines they need without unnecessary disruption to their care.

Our pharmacy team is on hand to answer medication-related questions, to explain your treatment, and to raise any concerns about your medicine with the prescribing team where needed. Patient safety and accurate dispensing are at the heart of everything we do.

1. electronic Medicines Compendium (emc). Actonel 35mg Film-Coated Tablets / Risedronate Sodium 35mg Tablets – Summary of Product Characteristics. www.medicines.org.uk/emc. Accessed June 2026.
2. British National Formulary (BNF). Risedronate sodium. bnf.nice.org.uk/drugs/risedronate-sodium. Accessed June 2026.
3. NHS. Risedronate. www.nhs.uk/medicines/risedronate. Accessed June 2026.
4. National Osteoporosis Guideline Group (NOGG). Clinical Guideline for the Prevention and Treatment of Osteoporosis. www.nogg.org.uk. Accessed June 2026.
5. Siris ES, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women. Mayo Clinic Proceedings. 2006;81(8):1013-1022. Published reference for adherence evidence.